Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery

This study has been completed.
Information provided by (Responsible Party):
Cara Therapeutics, Inc. Identifier:
First received: May 25, 2011
Last updated: July 24, 2012
Last verified: July 2012

The primary purpose of this study is to determine if CR845 is effective in treating the pain associated with a laparoscopic hysterectomy.

Condition Intervention Phase
Postoperative Pain
Drug: CR845
Drug: Placebo
Drug: CR 845
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-Center, Double-Randomized, Double Blind, Placebo Controlled Study to Evaluate the Analgesic Efficacy and Safety of Intravenous CR845 Dosed Preoperatively and Postoperatively in Patients Undergoing a Laparoscopic Hysterectomy

Resource links provided by NLM:

Further study details as provided by Cara Therapeutics, Inc.:

Primary Outcome Measures:
  • Total morphine consumption in the first 24 hours in patients who are re-randomized in the postoperative period. [ Time Frame: 24 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the efficacy of CR845 compared to placebo in reducing pain following laparoscopic hysterectomy [ Time Frame: Up to 24 hours ] [ Designated as safety issue: No ]
    Pain Intensity, Pain Relief and Patient Global Assessment Measures would be obtained.

  • To evaluate the effect of CR845 compared to placebo on the use of rescue opioid analgesics during the postoperative period [ Time Frame: Up to 24 hours ] [ Designated as safety issue: No ]
    Milligrams of Morphine consumed...

  • Proportion of patients requiring rescue morphine within the first 4 hours following completion of the surgical procedure. [ Time Frame: Up to 24 hours ] [ Designated as safety issue: No ]
    Number of patients requiring morphine rescue

Enrollment: 203
Study Start Date: July 2011
Study Completion Date: April 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CR 845
Use of peripheral kappa receptor agonist
Drug: CR845
CR845 0.04 mg/kg single intravenous dose administered preoperative
Other Name: Preemptive Active Dose
Drug: CR 845
CR845 0.04 mg/kg single intravenous dose administered postoperatively for pain
Other Name: Postoperative Active for Pain
Placebo Comparator: Placebo
Placebo Arm
Drug: Placebo
Matching Placebo given as a single intravenous dose administered preoperative
Other Name: Preemptive Placebo Dose
Drug: Placebo
Matching Placebo given as a single intravenous dose administered postoperatively for pain
Other Name: Postoperative Placebo for Pain

Detailed Description:

Currently, the most widely used drugs to treat pain after surgery are opiates, such as morphine. Morphine works mainly by activating one of several types of opiate receptors that control some of our pain sensation - the so-called mu opiate receptors. These receptors are located in many areas of the brain and also outside of the brain. By activating these receptors, morphine provides significant pain relief, but also causes side effects that limit its use. Some of these side effects include: respiratory depression or arrest (slowed or stopped breathing), sedation (a state of calmness or extreme relaxation), euphoria (an exaggerated feeling of physical and mental well-being), constipation, nausea, vomiting, and drug addiction.

In order to avoid the side effects of morphine and other mu opiates, the present experimental drug CR845 was designed to work at a different type of opiate receptor - called kappa - that can also provide pain relief, by acting on sensory nerves outside the brain. CR845 was designed to penetrate the brain much less than other opiate drugs, which should result in pain relief similar to that of morphine, but with fewer side effects. Because CR845 activates kappa receptors instead of mu receptors, the side effects are different than with a morphine-type drug. In particular, kappa opiates, such as CR845, do not cause respiratory depression or arrest, euphoria, constipation, drug tolerance, physical drug dependence or drug addiction. For these reasons, CR845 may present a distinct advantage over other opiates that are currently used for pain relief and post-operative pain in particular.


Ages Eligible for Study:   21 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Able to provide written informed consent prior to any study procedures;
  • Able to communicate clearly with the Investigator and staff;
  • Female between 21 and 65 years of age, inclusive;
  • Scheduled for elective laparoscopic hysterectomy under general anesthesia;
  • Negative result on serum pregnancy test at screening and negative urine pregnancy test at Baseline (for women of child-bearing potential only) and not currently breast feeding, or planning to do so within 30 days of dosing;
  • Negative urine drug screen for drugs of abuse at Screening and at Baseline;
  • American Society of Anesthesiologists (ASA) risk class of I to III;
  • Body mass index (BMI) between 17 and 40 inclusive.

Exclusion Criteria:

  • Has known allergies to opioids, or hypersensitivity to other materials (such as infusion line) or medications to be used in the study;
  • Has a known or suspected history of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)-diagnosed alcohol, opiate or other drug abuse or dependence within 12 months prior to screening;
  • Is unable to refrain from alcohol consumption for a period beginning 24 hours prior to surgery through the end of the Treatment Period;
  • Is scheduled to undergo a hysterectomy that will utilize any type of robotic technology and/or a concomitant surgical procedure that would produce a significantly greater degree of surgical trauma than the laparoscopic hysterectomy or laparoscopic assisted vaginal hysterectomy alone;
  • Has taken non-opioid analgesics (including cyclooxygenase-2 [COX-2] inhibitors) or nonsteroidal anti-inflammatory drugs (NSAIDs) within 12 hours of the Baseline assessments;
  • Has taken any opioid analgesics or used systemic steroids within 4 days of surgery OR has previously used opiates chronically for a period of ≥3 months;
  • Has used antipsychotics, antiepileptics, sedatives, hypnotics, or antianxiety agents, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants for < 30 days prior to surgery or had a dose change within the previous 30 days;
  • Has taken any prescription or over-the-counter medication within 3 days prior to surgery that, in the opinion of the Investigator, is expected to confound the analgesic response;
  • Has taken herbal agents or nutraceuticals (i.e., chaparral, comfrey, germander, gin bu huan, kava, pennyroyal, skullcap, St. John's wort, or valerian) 7 days prior to surgery;
  • In the opinion of Investigator shows clinical signs of hypovolemia;
  • Has an oxygen saturation < 92% on room air at Screening or prior to receiving the first infusion of study drug;
  • Has any history of clinically significant cardiovascular disease,
  • Has a clinically significant abnormal electrocardiogram (ECG) or a history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome);
  • Has a history of any serious medical conditions that in the opinion of the Investigator would preclude study participation;
  • Has serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, or gamma glutamyl transferase (GGT) >2.5 x the upper limit of normal (ULN) at screening;
  • Has bilirubin, blood urea nitrogen (BUN), or creatinine >1.5 x the reference ULN at Screening;
  • Has abnormally low hemoglobin < 10 mg/dl at Screening;
  • Has serum sodium levels > 146 mmol/L at Screening;
  • Has impaired renal function (creatinine clearance [CrCl] < 50 ml/min) at Screening;
  • Has a positive test for human immunodeficiency virus (HIV) or known history of HIV infection;
  • Has received another investigational drug within 30 days of scheduled surgery;
  • Has a significant chronic pain condition in areas unrelated to the operative site at the time of Screening that in the Investigator's opinion could confound the interpretation of study results
  Contacts and Locations
Please refer to this study by its identifier: NCT01361568

United States, Alabama
Shoals Clinical Research Associates
Florence, Alabama, United States, 35630
Mobile, Alabama, United States, 36608
Horizon Research Group
Mobile, Alabama, United States, 36606
Drug Research and Analysis Corp
Montgomery, Alabama, United States, 36106
Shoals Medical Trials, INC
Sheffield, Alabama, United States, 35660
United States, Arizona
Precision Clinical Trials
Phoenix, Arizona, United States, 85032
United States, California
Woodland Healthcare California Clinical Research, Inc
Davis, California, United States, 95616
Olive View-UCLA Medical Center
Sylmar, California, United States, 91342
United States, Florida
Visions Clinical Research
Boynton Beach, Florida, United States, 33472
Riverside Clinical Research
Edgewater, Florida, United States, 32132
University of Miami, Dept of
Miami, Florida, United States, 33136
United States, Kansas
Cypress Medical Research
Wichita, Kansas, United States, 67226
United States, New Jersey
Cooper University Hospital
Camden, New Jersey, United States, 08103
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27710
United States, Ohio
Ohio State University Medical, Dept of Anesthesia
Columbus, Ohio, United States, 43210
United States, South Carolina
Palmetto Clinical Research,
Greenville, South Carolina, United States, 29615
United States, Tennessee
Chattanooga Medical Research
Chattanooga, Tennessee, United States, 37404
United States, Texas
Texas Health Care, PLLC
Fort Worth, Texas, United States, 76104
Sponsors and Collaborators
Cara Therapeutics, Inc.
Principal Investigator: Steven Wininger, MD Precision Clinical Trials
  More Information

No publications provided

Responsible Party: Cara Therapeutics, Inc. Identifier: NCT01361568     History of Changes
Other Study ID Numbers: CR845 CLIN2002
Study First Received: May 25, 2011
Last Updated: July 24, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Cara Therapeutics, Inc.:
acute pain
visceral pain
kappa agonist
opioid analgesics
peripheral nervous system agents
physiological effects of drugs
post-operative complications

Additional relevant MeSH terms:
Pain, Postoperative
Postoperative Complications
Pathologic Processes
Signs and Symptoms
Peripheral Nervous System Agents
Physiological Effects of Drugs
Sensory System Agents
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses processed this record on April 22, 2014